M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
17.4 EUR
+0.06 (+0.35%)
Taking everything into account, M12 scores 6 out of 10 in our fundamental rating. M12 was compared to 30 industry peers in the Health Care Providers & Services industry. M12 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. M12 has a correct valuation and a medium growth rate. This makes M12 very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- M12 had positive earnings in the past year.
- M12 had a positive operating cash flow in the past year.
- Each year in the past 5 years M12 has been profitable.
- Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 8.73%, M12 belongs to the top of the industry, outperforming 96.67% of the companies in the same industry.
- M12 has a Return On Equity of 15.03%. This is in the better half of the industry: M12 outperforms 80.00% of its industry peers.
- M12 has a Return On Invested Capital of 13.44%. This is amongst the best in the industry. M12 outperforms 93.33% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for M12 is in line with the industry average of 6.46%.
- The last Return On Invested Capital (13.44%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
- M12 has a better Profit Margin (5.00%) than 90.00% of its industry peers.
- M12's Profit Margin has declined in the last couple of years.
- M12 has a better Operating Margin (8.52%) than 80.00% of its industry peers.
- M12's Operating Margin has declined in the last couple of years.
- M12 has a Gross Margin (19.29%) which is in line with its industry peers.
- In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
- M12 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, M12 has less shares outstanding
- The number of shares outstanding for M12 has been increased compared to 5 years ago.
- M12 has a worse debt/assets ratio than last year.
2.2 Solvency
- M12 has an Altman-Z score of 5.62. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of M12 (5.62) is better than 100.00% of its industry peers.
- The Debt to FCF ratio of M12 is 0.70, which is an excellent value as it means it would take M12, only 0.70 years of fcf income to pay off all of its debts.
- M12's Debt to FCF ratio of 0.70 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
- A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
- M12's Debt to Equity ratio of 0.05 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.62 |
ROIC/WACC1.83
WACC7.35%
2.3 Liquidity
- A Current Ratio of 2.06 indicates that M12 has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 2.06, M12 belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
- A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
- M12 has a Quick ratio of 1.35. This is amongst the best in the industry. M12 outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 10.36% over the past year.
- The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
- The Revenue has been growing slightly by 6.52% in the past year.
- The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
- The Earnings Per Share is expected to grow by 19.18% on average over the next years. This is quite good.
- The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 18.51, the valuation of M12 can be described as rather expensive.
- M12's Price/Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 26.94, M12 is valued a bit cheaper.
- A Price/Forward Earnings ratio of 15.00 indicates a correct valuation of M12.
- The rest of the industry has a similar Price/Forward Earnings ratio as M12.
- When comparing the Price/Forward Earnings ratio of M12 to the average of the S&P500 Index (23.94), we can say M12 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.51 | ||
| Fwd PE | 15 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, M12 is valued a bit cheaper than the industry average as 63.33% of the companies are valued more expensively.
- M12's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.8 | ||
| EV/EBITDA | 8.53 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- M12 has a very decent profitability rating, which may justify a higher PE ratio.
- M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.57
PEG (5Y)2.32
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 2.88%, M12 has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 1.73, M12 pays a better dividend. On top of this M12 pays more dividend than 86.67% of the companies listed in the same industry.
- M12's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.88% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (1/19/2026, 7:00:00 PM)
17.4
+0.06 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-18 2025-11-18
Earnings (Next)05-19 2026-05-19
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap341.74M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target28.05 (61.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.88% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.77%
PT rev (3m)3.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.51 | ||
| Fwd PE | 15 | ||
| P/S | 0.96 | ||
| P/FCF | 12.8 | ||
| P/OCF | 12.64 | ||
| P/B | 2.9 | ||
| P/tB | 12.44 | ||
| EV/EBITDA | 8.53 |
EPS(TTM)0.94
EY5.4%
EPS(NY)1.16
Fwd EY6.67%
FCF(TTM)1.36
FCFY7.81%
OCF(TTM)1.38
OCFY7.91%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.57
PEG (5Y)2.32
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.62 |
F-Score9
WACC7.35%
ROIC/WACC1.83
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year30.73%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
What is the valuation status for M12 stock?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for M12 stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 18.51 and the Price/Book (PB) ratio is 2.9.
What is the financial health of M1 KLINIKEN AG (M12.DE) stock?
The financial health rating of M1 KLINIKEN AG (M12.DE) is 8 / 10.